Biocept (BIOC) Announces Presentation of Positive Target-Selector Data in NSCLC at 2016 ESMO
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Biocept, Inc. (Nasdaq: BIOC) announces that clinical results from a study evaluating 40 patients with advanced non-small cell lung cancer (NSCLC) demonstrated up to 90% concordance between the Company's Target-Selector™ platform and tissue biopsy for the detection of actionable oncogene mutations and other validated cancer biomarkers. Analysis of a patient subset in the study showed that changes in both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), detected using Biocept's proprietary liquid biopsy assays, correlated significantly to response to systemic drug therapy in a majority of cases. The clinical data were presented at the 2016 European Society for Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark.
"In this dataset, Biocept's blood-based ctDNA assay demonstrated high concordance relative to tissue biopsy for the identification of actionable molecular alterations associated with non-small cell lung cancer," stated Oscar Arrieta, M.D., the study's lead investigator, and Coordinator of Clinical Lung Cancer and Thoracic Tumor and Head of the Laboratory of Personalized Medicine at the National Cancer Institute of Mexico. "Given these findings, the Target Selector™ technology appears to be a viable noninvasive alternative for establishing mutational status, and for identifying secondary resistance mutations such as EGFR T790M in patients who progress on first-line tyrosine kinase inhibitor therapy. Clear changes observed in the level of detectable mutant allele frequency after treatment suggest that this liquid biopsy method holds promise to be used for real-time monitoring of patients' clinical status."
In the study, analysis with Biocept's Target Selector™ ctDNA platform found that the T790M resistance mutation was present in the plasma of 50% of patients with clinical progression when treated with tyrosine kinase inhibitors.
"These study results validate the ability of our Target Selector™ tests to comprehensively profile a patient's cancer, and further demonstrate the high sensitivity and specificity of our dual ctDNA and CTC assay platforms," said Biocept's Senior Vice President and Chief Scientific Officer, Lyle Arnold, Ph.D.
"We are pleased that these findings, generated by world-class collaborators from both academia and biopharma, were presented at the Annual ESMO Congress in Copenhagen," said Biocept's President and CEO Michael Nall. "We continue to build the body of clinical evidence supporting the utility of our proprietary liquid biopsy platform, as we increase physician adoption of our technology and help patients in their fight against cancer."
Physicians interested in ordering Biocept's liquid biopsy tests for cancer biomarkers should contact Customer Service at 858-320-8206, or visit http://biocept.com/medical-professionals/.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Teleflex (TFX) to Acquire Vascular Solutions (VASC) in $1B Deal
- SoTHERLY Hotels (SOHO) Approves $10M Stock Buyback Plan
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!